Dive Into Dollar Tr...
Health Care: Drugs
Sarepta Therapeutics Inc (SRPT: NASDAQ)
$36.91 1.40 | 3.94%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 36.91 |
| 52 Week High | 45.00 |
| 52 Week Low | 3.30 |
| Avg. Daily Vol. (Mil) | 1.98 |
| Beta (3 year) | 0.94 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,177.78 |
| Shares Out (Mil) | 31.91 |
| Float (Mil) | 31.73 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.70 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.02 |
| Total Debt / Equity | 0.02 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 38.50 |
| Price/Book | 13.49 |
| Price/Cash Flow | -7.30 |
| Per Share Data | |
| Earnings | -5.67 |
| Sales | 0.96 |
| Book Value | 2.74 |
| Cash Flow | -5.07 |
| Business Summary | |
|---|---|
| Sarepta Therapeutics Inc discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen. | |
| General Information | |
| 215 First Street
Suite 007 Cambridge, MA 02142 |
|
| www.sareptatherapeutics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 103 | |
| CEO: Mr. Christopher Garabedi | |
| Short Interest | |
| Current Month (Mil) | 8.91 |
| Previous Month (Mil) | 7.83 |
| Short Interest Ratio (Days) | 3.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -84.50 |
| Return on Investments | -183.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with SRPT
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserWatch
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- UserKJP Save Stockpickr Fund
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
Latest SRPT Headlines from TheStreet
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.16.13 | 05:05 pm
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.01.13 | 05:05 pm
- A DMD Expert and Mother Calls For Eteplirsen's Rapid Approval 04.26.13 | 09:04 am
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard 04.19.13 | 05:04 pm
- Stocks Rebound Mirrors Markets After Madrid, London Bombings 04.16.13 | 04:04 pm
- Sarepta Stock Gaps Down On Today's Open (SRPT) 04.16.13 | 09:04 am
- A Proactive FDA Is Already Reviewing Sarepta's Muscular Dystrophy Drug 04.15.13 | 05:04 pm
Press Releases for SRPT
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
- Over 25 Companies To Present At Emerald Groundhog Day Investment Forum - Business Wire 02.05.13 | 10:02 am
Partner Headlines for SRPT
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In - Seeking Alpha 04.11.13 | 09:04 am
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- Sarepta Therapeutics Setting Up For Another Move Upward - Seeking Alpha 01.31.13 | 09:01 am
- Raptor To Rise On Proven Strategy & Upcoming FDA Decision - Seeking Alpha 12.28.12 | 09:12 am
- UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential - Benzinga 11.26.12 | 09:11 am
- Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for Treatment of Duchenne Muscular Dystrophy - Benzinga 10.12.12 | 04:10 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Benzinga Mid-Morning Market Update - Benzinga 10.05.12 | 01:10 pm
- 3 Interesting Moves In Biotech Stocks From Wednesday - Seeking Alpha 10.04.12 | 09:10 am
